FoundationOne CDx is a FDA-approved broad companion diagnostic (CDx) that is clinically and analytically validated for solid tumors. The test provides next-generation DNA sequencing analysis of patient’s tumor to provide physicians with clinically actionable information — both to consider appropriate therapies for patients and understand results with evidence of resistance. Microsatellite instability (MSI) and tumor mutational burden (TMB) is included in every test and can help inform immunotherapy decisions.

You can also order PD-L1 immunohistochemistry (IHC) testing to help inform your therapy decision.